Skip to main content
Premium Trial:

Request an Annual Quote

Incyte, CV Therapeutics Expand Heart Disease Collaboration

NEW YORK, Aug 27 – Incyte and CV Therapeutics said Monday they had agreed to work together to study the role genes play in heart disease, expanding a joint research effort that began in 1998.

Under the terms of the new agreement, the companies, both of Palo Alto, Calif., said they would focus on pinpointing genes associated with atherosclerosis and coronary artery disease.

CV Therapeutics will be responsible for developing biological models for studying the genetic aspect of cardiovascular disease and will supply mRNA from the models to Incyte. In turn, Incyte will generate RNA expression data using its microarray technology.

"Our collaboration with Incyte has been successful in identifying new therapeutic targets such as the ABC1 gene and other undisclosed potential targets, and we look forward to continuing this relationship with our scientific colleagues," Louis Lange, CEO of CV Therapeutics, said in a statement. 

"We are committed to studying cardiovascular disease in a genome-wide fashion in order to identify and develop new targets," he added. 

Financial terms of the deal were not disclosed.

The companies said that under their previous collaboration they had made a number of discoveries, including determining the ABC1 protein’s role in pumping cholesterol out of cells. 

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.